UPDATE 2-U.S. FDA approves Novartis' leukemia treatment

April 28 (Reuters) - The U.S. Food and Drug Administration approved Novartis AG's Rydapt as an initial treatment for acute myeloid leukemia (AML) as well as certain other blood disorders, the agency said on Friday.